News and Announcements
Viralytics Ltd (ASX:VLA) – Shareholder and Investor Presentation
- Published April 03, 2013 12:07PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Viralytics Ltd (ASX:VLA) is an Australian ASX listed biotechnology cancer company focussed on developing viruses which selectively target cancer cells.
OVIERVIEW:
- Lead product is CAVATAK™ with broad anti-cancer activity
- CAVATAK™ program:
- Completed five Australian Phase 1 trials with 28 patients
- Current US Phase 2 trial in melanoma patients
- Planned Phase 1/2 UK trial in lung, prostate, bladder and melanoma cancer patients
- Potential low toxicity unlike traditional chemotherapies
- Achieved GMP manufacture
- Robust intellectual property/patent portfolio
- Big Pharma interest: 2011 US$1.0 billion Amgen/Biovex deal
- One of only 2 listed oncolytic virus companies globally
- Experienced Board/Management and Scientific team
To read the full ASX announcement, please download the document below.
Company Updates
Built on discipline, not complexity: inside an ASX equities income strategy
Haydn Froggatt and Zac Brabin have decades of derivatives experience between them and access to almost any strategy in the market. They use two of the simplest structures available, and wrote 202 positions with them last year. Published by Fairway Capital Management. Based on an interview with co-founders Haydn Froggatt and Zac Brabin. Two traders, […]
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
Backed By Leading Investment Groups and Family Offices
